Your browser doesn't support javascript.
loading
Differentiation of Dunn osteosarcoma cells in response to dibutyryl cyclic 3',5'-adenosine monophosphate.
Kanamori, M; Matsui, H; Yudoh, K; Maeda, A; Kadowaki, K M; Tsuji, H; Ochiai, H; Tatezaki, S.
Afiliación
  • Kanamori M; Department of Orthopedic Surgery, Toyama Medical and Pharmaceutical University, Japan.
J Cancer Res Clin Oncol ; 119(6): 323-8, 1993.
Article en En | MEDLINE | ID: mdl-8383687
ABSTRACT
We investigated the effects of dibutyryl cyclic adenosine 3',5'-monophosphate (Bt2cAMP) on the differentiation of Dunn osteosarcoma cells. Flow-cytometric analysis and DNA synthesis assay showed that Bt2cAMP decreased the cell population in the S phase in a time- and dose-dependent manner. Also, the cells showed distinct morphological and functional alterations; the cell morphology changed to a fibroblast-like appearance with long and thin protoplasmic processes, the knobs or blebs on both the cell membrane and nuclear membrane disappeared and the intracellular alkaline phosphatase activity increased. Moreover, Bt2cAMP-treated cells secreted a large quantity of fibronectin, which was deposited on the extended cell surface in the culture medium. Thus, Dunn osteosarcoma cells are differentiated morphologically and functionally by Bt2cAMP, and might be transformed to benign precursor cells.
Asunto(s)
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Osteosarcoma / Bucladesina Límite: Animals Idioma: En Año: 1993 Tipo del documento: Article
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Osteosarcoma / Bucladesina Límite: Animals Idioma: En Año: 1993 Tipo del documento: Article